Investor Relations

Company Profile

ResApp Health Limited (ASX:RAP) is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease on smartphones without the need for additional hardware. ResApp’s core technology uses sound to diagnose respiratory diseases including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease and asthma.

Registered Office

Level 12, 100 Creek St
Brisbane, QLD 4000

Board of Directors

Dr Roger Aston – Non-Executive Chairman
Dr Tony Keating – Chief Executive Officer and Managing Director
Nathan Buzza – Non-Executive Director
Chris Ntoumenopoulos – Non-Executive Director

Listing

Australian Securities Exchange
ASX code: RAP

Share price

Please refer to the ASX website for current share price and history.

Share Registry

Link Market Services Limited
Level 12 QV1 Building
250 St Georges Terrace
Perth WA 6000

Investor Relations Contact

Brian Leedman
VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au